Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab Combined With Chemotherapy in Locally Advanced Gastroesophageal Junction Tumors
NCT07092449Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of pucotenlimab in gastroesophageal junction adenocarcinoma, sponsored by Tangdu Hospital. Primary endpoint: Pathological Complete Response at 2 weeks. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07092449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07092449.